ALK inhibitor 2 is a new-type and selective inhibitor for the ALK kinase.

ALK5-IN-26 (EX-22) is an ALK (Activin receptor-like kinase) inhibitor. ALK5-IN-26 inhibits ALK5 (IC50 ≤ 1 nM).

ALK-IN-23 is a potent inhibitor of ALK, acting on ALKWT (IC50: 1.6 nM), ALKL1196M (IC50: 0.71 nM) and ALKG1202R (IC50: 1.3 nM). -IN-23 has inhibitory effects on cancer cell migration and colony formation in vitro. In the H2228 xenograft nude mouse model, ALK-IN-23 showed good anti-tumour effects with low toxicity.

ALK5-IN-8 is a highly effective inhibitor of TGFβRI (ALK5). It hinders the phosphorylation of ALK5 on downstream signaling proteins (Smad2 or Smad3) by obstructing the interaction between TGFβRI and ligands. Consequently, it disrupts or prevents TGF-β signaling. ALK5-IN-8 shows promise in the study of diverse diseases associated with ALK5-mediated pathways[1].

ALK5-IN-6 is a potent inhibitor of ALK5. ALK5-IN-6 has potential for TGF-β-related diseases and conditions, including but not limited to tumors, inflammatory diseases, fibrotic diseases, autoimmune diseases, etc.Among them, transforming growth factor β (TGF-β) is a multifunctional cytokine involved in the regulation of cell proliferation, differentiation and apoptosis in an autocrine, paracrine and endocrine manner through a complex receptor signaling pathway on the cell surface.

ALK5-IN-9 is a potent, orally active inhibitor of TGFβRI (ALK5). ALK5-IN-9 inhibits ALK5 autophosphorylation (IC50: 25 nM) and inhibits NIH3T3 cell activity (IC50: 74.6 nM). ALK5-IN-9 has shown research potential in cancer diseases.

ALK2-IN-5, a pyrazolopyrimidine compound, serves as an inhibitor of ALK2 and FGFR, targeting disorders linked with their activity, including cancer [1].

ALK5-IN-7 is an effective inhibitor of ALK5. Transforming growth factor β (TGF-β) is a multifunctional cytokine that is involved in regulating cell proliferation, differentiation, and apoptosis through autocrine, paracrine, and endocrine pathways using complex receptor signaling pathways on the cell surface. ALK5-IN-7 has the potential to perform research on TGF-β-related diseases and conditions (including but not limited to tumor, fibrosis, inflammatory diseases, autoimmune diseases, etc.).

Benzalkonium chloride (Alkyldimethylbenzylammonium chloride) is a cationic surface-acting agent containing the quaternary ammonium group. It has three main categories of use: as a cationic surfactant, a biocide, and phase transfer agent in the chemical industry. This compound is a heterogeneous mixture of alkylbenzyldimethylammonium chlorides of multiple even-numbered alkyl chain lengths.

C15AlkOPP Tetrabutylamine salt is a “clickable” alkyne-modified analogs of the lipid substrates farnesyl diphosphate (FPP).

PC Biotin-PEG3-alkyne is an ADC linker, cleavable 3-unit PEG, which can also be used to synthesize antibody drug conjugates (ADCs).

C15AlkOPP Tetrabutylamine salt (1：2) is an FPP analogue, bearing an alkyne group to allow for post-prenylation protein labeling. C15AlkOPP Tetrabutylamine salt (1：2) can be used for Prenylomic analysis

Desalkylterbuthylazine is used as pharmaceutical intermediates.

Tralkoxydim (Tralkoxydime) is an alkyl ketone herbicide. Tralkoxydim works as an ACCase inhibitor.

Butanoic acid, 4-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]amino]- (4-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]butanoic acid) is a Cereblon ligand with alkyl linker and terminal acid for onward chemistry.

Itaconate-alkyne (ITalk) is a bioorthogonal probe for quantitative and site-specific chemoproteomic profiling of itaconate in inflammatory macrophages and enables biochemical evaluation and proteomic analysis of its direct targets.

Labradimil is a bradykinin B2 receptor agonist. Labradimil increases the permeability of human brain microvascular endothelial cell monolayers. Labradimil enhances delivery of hydrophilic chemotherapeutics and increases survival in rats with metastatic tu

AZD-3463 (ALK/IGF1R inhibitor) , an orally bioavailable ALK inhibitor (Ki: 0.75 nM), can inhibit IGF1R with equivalent potency.